Navigation Links
Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
Date:12/20/2007

-Five New Clinical Trial Sites Recently Initiated To Support Ongoing

Trials- -Clinical Data Expected in 2008 from Seven Ongoing or Planned Clinical

Trials, Including Four Phase II Trials in Major Disease Indications- -Revenues Plus Cash On-Hand Expected to Provide Sufficient Resources to

Advance Programs as Planned-

TUSTIN, Calif., Dec. 20 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today confirmed that its plans for advancing all three of its lead clinical programs in 2008 remain on track. The combination of revenues expected to be generated by Avid, the company's contract manufacturing subsidiary, plus the more than $26 million in cash on- hand reported as of October 31, 2007, should provide sufficient resources to advance these programs. To enhance enrollment rates and accelerate the generation of clinical data, Peregrine recently added additional clinical trial sites to all three of the core clinical programs.

"We believe data from our lead clinical programs will be the key value drivers for Peregrine in 2008, and I am pleased to report that our ambitious clinical plans for advancing all three anti-cancer and antiviral clinical programs in calendar year 2008 are proceeding as planned," said Peregrine president and CEO Steven W. King. "With at least seven clinical studies, including four Phase II trials, slated for 2008, we anticipate that the coming year will provide us with many opportunities to share clinical data with the medical community, potential partners and investors." <
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2008)...- Effective immediately, SpectraCell,...amin C (ascorbate) using,its proprietary FIA(TM) (...s test enables a clinician to diagnose specific vi... deficiency symptoms appear. The demand for,testin...n recent years and,represents an important additio...
(Date:7/2/2008)...coming soon to Bioniche,s growing line of injectab...FOREST, Ill., July 2 /- Bioniche Phar...able pharmaceuticals, announced today,the acquisit...ct line,including:, -- ENLON(R) (edrophonium c...NLON-PLUS(R) (edrophonium chloride, USP and atropi...
(Date:7/2/2008)...velops new therapies based on cells manufactured f...provide funding round, SALT LAKE CITY and HAMBURG... biotechnology company at the forefront of innovat...ey injury, today announced the closing of a,$14.5M... Sciences with Novo,A/S joining the syndicate., "...
(Date:7/2/2008)...e Commercialization of Expanded Portfolio of Vascu...OUVER, British Columbia, July 2 /- Ne...Corp. (TSXV: MEV), a company developing and,market...nnounced its name,change and the expansion of its ...quisition of two vascular product development comp...
Breaking Biology Technology:SpectraCell Laboratories Now Measures Vitamin C 2Bioniche Pharma Acquires Baxter's ENLON(R) and ENLON-PLUS(R) 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 3Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing 2Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing 3Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing 4
... Other important parameters for optimizing electr..., , Field strength , ... Number of , field pulses , ...on buffer , Influence , of...temperature , Influence , ...
... Other important parameters for optimizing electr..., , Field strength , ... Number of , field pulses , ...on buffer , Influence , of...temperature , Influence , ...
... Other important parameters for optimizing electr... , Field strength , ... Number of , field pulses , ...n buffer , Influence , of ...emperature , Influence , o...
... It is common knowledge in most laboratories that...han DNA. Unlike Deoxyribonucleases (DNases), which... therefore easily be inactivated with chelating ,...) have virtually no cofactor , requirements...o the , phosphodiester linkages in RNA as a...
Other Biology Technology:Optimizing electroporation parameters 2Optimizing electroporation parameters 2Optimizing electroporation parameters 3Optimizing electroporation parameters 4Optimizing electroporation parameters 5Decontamination and inhibition of ribonucleases 2Decontamination and inhibition of ribonucleases 3Decontamination and inhibition of ribonucleases 4
(Date:7/3/2008)...umers yet their properties have been difficult to ...drain on our limited natural resources. Until now ...ratory (NPL) are working towards producing the wor... naturalness. The results could help make syntheti...r senses as being fully equivalent to the ,real th...
(Date:7/3/2008)...ape and size of microscopic three-dimensional stru... biological chemist Jason Shear and his former gra...as at Austin. , Shear and Kaehr fabricated a var..., known as hydrogels, and have shown that they can...mistry of the environment in which they were built...
(Date:7/2/2008)...ed the first clear example of how climate extremes...normally tolerated singly may converge and bring a...ssued June 25 by PLoS ONE, an online peer-review...s of canine distemper virus (CDV) in 1994 and 2001...ngeti lions. CDV cycles periodically within the Se...
(Date:7/2/2008)... The FASEB Journal provide more evidence that if ...an improve. According to MIT scientists, dietary n...t formula to eggs increase brain synapses and impr...will, like those of experimental animals, respond ...apses and thus restoring cognitive abilities," sai...
Breaking Biology News(10 mins):Scientists set out to measure how we perceive naturalness 2Scientists set out to measure how we perceive naturalness 3'Smart' materials get smarter with ability to better control shape and size 2'Smart' materials get smarter with ability to better control shape and size 3Two Year Study Confirms SUPPRELIN 28R 29 LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 5106 1Two Year Study Confirms SUPPRELIN 28R 29 LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 5106 2Two Year Study Confirms SUPPRELIN 28R 29 LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 5106 3Two Year Study Confirms SUPPRELIN 28R 29 LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 5106 4Two Year Study Confirms SUPPRELIN 28R 29 LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 5106 5ATS Medical Announces Record Quarterly Revenue and Gross Profit 5102 1ATS Medical Announces Record Quarterly Revenue and Gross Profit 5102 2ATS Medical Announces Record Quarterly Revenue and Gross Profit 5102 3ATS Medical Announces Record Quarterly Revenue and Gross Profit 5102 4ATS Medical Announces Record Quarterly Revenue and Gross Profit 5102 5ATS Medical Announces Record Quarterly Revenue and Gross Profit 5102 6ATS Medical Announces Record Quarterly Revenue and Gross Profit 5102 7ATS Medical Announces Record Quarterly Revenue and Gross Profit 5102 8ATS Medical Announces Record Quarterly Revenue and Gross Profit 5102 9Adopted Children at Slightly Higher Mental Health Risk 18457 1Adopted Children at Slightly Higher Mental Health Risk 18457 2Adopted Children at Slightly Higher Mental Health Risk 18457 3Preference for alcohol in adolescence may lead to heavy drinking 18453 1Preference for alcohol in adolescence may lead to heavy drinking 18453 2
... People are known to differ markedly in their resp...rpinnings of these differences have remained diffi...a genetic difference in a so-called clock gene, PE... the effects of sleep deprivation. The findings, r...agues at the University of Surrey,s Sleep Research...
... Using a unique weaving machine of their design, D...ated a three-dimensional fabric "scaffold" that co...epair damaged joints with the patient,s own stem c...e scaffold could be used in clinical trials within...duate student in the Orthopedic Bioengineering Lab...
... Researchers have found evidence that rats are cap...owledge of their own cognitive states. This abilit... assess or reflect on one,s own mental processes, ... primates. The findings are reported by Allison Fo...gia and appear online in the journal Current Biolo...
... In 2005, the overall cost of patients, time spent... after diagnosis, according to a new study in the ...ncer Institute . The time costs for the 11 cancers...aried widely, they write. , Several studies have ... but few have attempted to include a patient,s tim...
Other Biology News:Individual differences in a clock gene predict decline of performance during sleep deprivation 2Woven scaffolds could improve cartilage repair 2Metacognition: Faced with a test, rats can check their knowledge first 2Study calculates patient time costs associated with cancer care 2Study calculates patient time costs associated with cancer care 3
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-MSC 2 x 109 cells
Agarose overlays are commonly used in baculovirus plaque assays. Many commercial "DNA grade" agaroses either contain contaminants that are toxic to insect cells or lack the physical characteristics r
AgarPlaque Plus Agarose 50 grams
Dithiothreitol, 1M from Upstate
Biology Products: